Figure 2
From: Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa
Serological pattern of the person infected by the HTLV-3 Pyl43 strain. (A) Western Blot from Genelabs Diagnostics (HTLV BLOT 2.4 version) and (B) a line immunoassay (INNO-LIA HTLV confirmation Immunogenetics). The HTLV 2.4 western blot kit is based on strips incorporating HTLV-1/2 native viral antigens (originating from HTLV-1 infected cells) to which HTLV-1 (MTA-1) or HTLV-2 (K55) gp46s or HTLV-1 and HTLV-2 (GD21) gp21 recombinant proteins have been added [11]. The INNO LIA kit uses only recombinant antigens and synthetic peptides derived from both HTLV-1 and HTLV-2 proteins sequences. Whereas gag p19 I/II corresponds both to a recombinant protein and synthetic peptides being recognized by anti HTLV-1 and HTLV-2 immune sera, env gp46 I/II corresponds only to synthetic peptides recognized by anti HTLV-1 and HTLV-2 immune sera. env gp46 II corresponds to synthetic peptides specific of HTLV-2 [12]. (A, B) Lane 1: HTLV-1 positive control; lane 2: HTLV-2 positive control; lane 3: STLV-3 positive control (STLV-3604 strain); lane 4: STLV-3 positive control (STLV-3F3); lane 5: HTLV-1/2 negative control; lane 6: plasma from the person infected by HTLV-3 (Pyl43 strain).